BeyondSpring Inc. (NasdaqCM: BYSI)
Health Care · Biotechnology · US
$0.56
-7.66% today · -67.9% 1Y
BeyondSpring Inc. (NasdaqCM: BYSI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $22.99M and employs 44 people.
Over the last twelve months the share price has lost 67.9%, trading between 0.56 and 2.44.
Tweenvest scores BeyondSpring Inc. across four factors: quality 30/100, value 33/100. Its strongest factor is value.
BYSI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $22.99M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- -0.21
- 52-week high
- $2.44
- 52-week low
- $0.56
- Avg volume (3M)
- —
- Shares outstanding
- 41.12M
- Employees
- 44
- Next earnings
- —
About BeyondSpring Inc.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
- ISIN
- KYG108301006
- Founded
- 2010
- Listed since
- Mar 9, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GeneMatrix Inc.KOSDAQ: A109820 | $23.69M | ₩1,549.00 | -9.94% |
| Transgenic Group Inc.TSE: 2342 | $23.63M | ¥224.00 | -4.27% |
| Evaxion A/SNasdaqCM: EVAX | $23.60M | $2.83 | -7.82% |
| RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S.IBSE: RTALB | $23.42M | TL2.32 | -10.77% |
| FF EAI Robotics Ecosystem Inc.NasdaqCM: FFR | $22.87M | $1.13 | +13.00% |
| Grace Breeding LtdTASE: GRAC | $22.64M | ₪16.47 | +1.92% |
| Arterra Bioscience S.p.A.BIT: ARBS | $22.59M | €3.03 | +0.33% |
| MaaT Pharma SAENXTPA: MAAT | $22.54M | €1.07 | +0.56% |
Figures last refreshed Oct 18, 2026.